5-Amino-1MQ
/five-ah-MEE-no one M · Q/aka 5-amino-1-methylquinolinium, 5A1MQ, NNMT inhibitor
A small molecule, not a peptide, that blocks the enzyme NNMT and reduced fat mass in obese mice.
5-Amino-1MQ: educational research discussion. Not medical advice. Not a protocol for you.Details
- Reported range
- 50–150 mg daily
- Frequency
- Once daily
- Cycle length
- Not standardized
- Half-life
- Unknown in humans
- Route
- Oral
Reported figures describe what is published or discussed. None of them is a dose for you.
Mechanism
What it is proposed to do
NNMT (nicotinamide N-methyltransferase) uses SAM to methylate nicotinamide, a form of vitamin B3 that feeds NAD+ production. Knocking NNMT down in mice protected them from diet-induced obesity. 5-Amino-1MQ, a methylquinolinium compound, blocks the enzyme. In cultured fat cells it lowered the NNMT product 1-MNA, raised NAD+ and SAM, and suppressed fat synthesis. None of this has been measured in people.
- 01
5-Amino-1MQ
Small molecule (methylquinolinium), not a peptide
established - 02
NNMT blocked
Selective against related enzymes in lab assays
proposed - 03
NAD+ ↑ · SAM ↑ · 1-MNA ↓
Measured in cultured fat cells
proposed - 04
Less fat mass in obese mice
11- to 28-day studies; food intake unchanged
proposed
Half-life. Unknown in humans. A 2024 mouse study measured pharmacokinetics after IV, oral and SC dosing. No human data exist.
Dosing & cycles
What is reported, and where it comes from
Numbers below are labeled FDA label, clinical trial range or commonly reported range. They describe the published and discussed landscape. They are not instructions and not a protocol for you.
Dosing studio
Every figure is labeled by where it comes from.
Scale view: Commonly reported oral range
Probe at 100 mg: inside the reported band (50–150 mg). Drag it to read the scale. It does not pick a number for you.
Typical cycle, as a calendar
Community pattern: daily oral block
Not standardized
Daily oral use for a block of weeks. The 8-week block shown is illustrative. Mouse studies ran 11 to 28 days, and no human data define a length, a break or a safe duration.
Cycle patterns
Community pattern: daily oral block
Daily oral use for a block of weeks. The 8-week block shown is illustrative. Mouse studies ran 11 to 28 days, and no human data define a length, a break or a safe duration.
Stacks
What it gets combined with
Why people pair things, and what nobody has tested.
NAD stack
3 compounds- Why people combine these
- Pitched as a two-way NAD+ push: supply more precursor, and block an enzyme that diverts nicotinamide.
- Caution
- Neither the pairing nor 5-amino-1MQ alone has human data. More NAD+ in a mouse fat cell is not a measured benefit in a person.
- What is unknown
- No published human data on this combination: dosing, interactions and long-term effects are all unstudied.
Fat-loss layering
3 compounds- Why people combine these
- Added to a GLP-1 drug in hopes of breaking a plateau.
- Caution
- The GLP-1 drug has the trials. 5-amino-1MQ adds an unknown with no interaction data.
- What is unknown
- No published human data on this combination: dosing, interactions and long-term effects are all unstudied.
Evidence
How much of this is known
Evidence grade
D
Little useful signal
Mechanism speculation, marketing, or almost no useful human signal.
How we gradeGraded D. A coherent mechanism and a handful of mouse studies, mostly from one research group and its spin-out company. No human data of any kind.
Human trial status
None. There are no published or registered human trials. The evidence is mouse and cell work, mostly from one University of Texas Medical Branch group and its spin-out company. In an 11-day study in diet-induced obese mice, treated animals lost about 5% of body weight while controls gained 1.4%, with no change in food intake. A 28-day mouse study reported better insulin sensitivity and less liver fat. In old mice, the compound improved muscle regeneration after injury.
Limitations
- No human data: no pharmacokinetics, no safety, no efficacy.
- Most studies come from one research group with a declared commercial interest (Ridgeline Therapeutics).
- The key obesity study dosed by injection. Community use is oral.
- A few percent of weight loss in mice over days does not predict human outcomes.
Sources to read
- Kraus D et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (Nature 2014)
- Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice (Biochem Pharmacol 2018)
- Neelakantan H et al. NNMT inhibitor activates senescent muscle stem cells in aged mice (Biochem Pharmacol 2019)
- Sampson CM et al. NNMT inhibition plus reduced-calorie diet in obese mice (Sci Rep 2021)
- Babula JJ et al. NNMT inhibition mitigates obesity-related metabolic dysfunction, with mouse pharmacokinetics (Diabetes Obes Metab 2024)
Links open PubMed, DailyMed, FDA or trial-registry searches. We do not cite what we have not described accurately.
Safety
Side effects, cautions, status
Commonly reported effects
- No human safety data exist. Short mouse studies reported no obvious adverse effects, which says little about people.
- NNMT sits in methylation and NAD+ pathways that touch many tissues. Long-term effects of blocking it are unknown.
- Doses discussed online have no human pharmacokinetic basis.
- Product quality is unverified: no regulator tests the identity, purity or dose of gray-market product.
Who should be extra cautious
- Tested athletes. Prohibited at all times (WADA S0).
- Pregnancy or breastfeeding. No data at all.
- Liver disease. NNMT is abundant in the liver. The effect of blocking it in a diseased liver is untested.
- Anyone on prescription metabolic drugs. No interaction data.
Legal & regulatory status
Not approved as a drug anywhere, and not in registered clinical development as far as public registries show. Supplement-style marketing online does not mean FDA has reviewed it.
WADA. Prohibited at all times under S0 (non-approved substances), which covers compounds with no approval for human therapeutic use.
Storage & handling, high level
Sold as a powder or capsules, not as a lyophilized peptide. We found no published stability data for consumer products. Identity and purity are the bigger unknowns.
Reconstitution and injection technique are clinical skills. The reconstitution calculator does arithmetic only.
FAQ
Questions people ask about 5-Amino-1MQ
Is 5-amino-1MQ a peptide?
Has it been tested in humans?
Does it raise NAD+?
Why is it WADA-prohibited if it is sold like a supplement?
The monthly Evidence Brief
Keep up with the evidence
One email a month: new trials, grade changes and FDA or WADA updates across the whole atlas, 5-Amino-1MQ included. You get the free guide right away.
Free guide · PDF
10 Peptide Claims, Fact-Checked
13 pages · sent to your inbox right away
Email only. Unsubscribe from any email in one click. We do not sell or rent your address. Nothing we send is medical advice. Privacy